Top Markets
Coin of the day
National Graphite Corp. National Graphite Corp.

National Graphite Corp.

NGRC
Rangering i aksjer #35948
National Graphite Corp. (NGRC), operating through its subsidiary Biotech... National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.
Aksjekurs
$0.021
Sist synkronisert: 2026-08-13
Markedsverdi
$3.24M
Endring (1 dag)
0.00%
Endring (1 år)
-46.15%
Land
US
Handel National Graphite Corp. (NGRC)
Inntekter for National Graphite Corp. (NGRC)
Inntekter i 2026 TTM: 0
Ifølge National Graphite Corp. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for National Graphite Corp. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter